%0 Journal Article
%T An overview of circulating and urinary biomarkers capable of predicting the transition of acute kidney injury to chronic kidney disease.
%A Berezin AE
%A Berezina TA
%A Hoppe UC
%A Lichtenauer M
%A Berezin AA
%J Expert Rev Mol Diagn
%V 24
%N 7
%D 2024 Jul 15
%M 39007888
%F 5.67
%R 10.1080/14737159.2024.2379355
%X <B>UNASSIGNED: </B>Acute kidney injury (AKI) defined by a substantial decrease in kidney function within hours to days and is often irreversible with higher risk to chronic kidney disease (CKD) transition.<BR><B>UNASSIGNED: </B>The authors discuss the diagnostic and predictive utilities of serum and urinary biomarkers on AKI and on the risk of AKI-to-CKD progression. The authors focus on the relevant literature covering evidence of circulating and urinary biomarkers' capability to predict the transition of AKI to CKD.<BR><B>UNASSIGNED: </B>Based on the different modalities of serum and urinary biomarkers, multiple biomarker panel seems to be potentially useful to distinguish between various types of AKI, to detect the severity and the risk of AKI progression, to predict the clinical outcome and evaluate response to the therapy. Serum/urinary neutrophil gelatinase-associated lipocalin (NGAL), serum/urinary uromodulin, serum extracellular high mobility group box-1 (HMGB-1), serum cystatin C and urinary liver-type fatty acid-binding protein (L-FABP) were the most effective in the prediction of AKI-to-CKD transition regardless of etiology and the presence of critical state in patients. The current clinical evidence on the risk assessments of AKI progression is mainly based on the utility of combination of functional, injury and stress biomarkers, mainly NGAL, L-FABP, HMGB-1 and cystatin C.